Since most leukemia cells are associated with the positive expression of specific antigens (such as CD123, CD33, CD96 and CLL-1) (72), targeted immunotherapy, including monoclonal antibodies (73) and bispecific antibodies, is currently in the clinical evaluation stage. Here, CD33 is linked to leukemia.